Biomarker data justify first-line Vectibix in colorectal cancer
This article was originally published in Scrip
Executive Summary
A new analysis of Phase II data for Amgen's Vectibix (panitumumab) at the 50th Annual American Society of Clinical Oncology (ASCO) Meeting on 31 May show a substantial benefit over Avastin (bevacizumab) and reinforce therapy's recent first-line colorectal cancer approval.